List of Excipients in Branded Drug MIDODRINE HCL

Generic Drugs Containing MIDODRINE HCL

Company	Ingredient	NDC	Excipient
Eon Labs Inc	midodrine hydrochloride	0185-0040	CELLULOSE, MICROCRYSTALLINE
Eon Labs Inc	midodrine hydrochloride	0185-0040	MAGNESIUM STEARATE
Eon Labs Inc	midodrine hydrochloride	0185-0040	SILICON DIOXIDE
Eon Labs Inc	midodrine hydrochloride	0185-0040	STARCH, CORN
Rebel Distributors Corp	midodrine hydrochloride	21695-181	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in MIDODRINE HCL?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE
1	FD&C BLUE NO. 2
2	MAGNESIUM STEARATE
1	SILICON DIOXIDE

Midodrine HCl Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Midodrine hydrochloride is a mature, genericized oral drug with limited patent-driven pricing power. The strongest commercial opportunities are differentiated oral delivery systems, supply-reliable tablets, and formulations for patients who cannot swallow conventional tablets. Excipient selection should prioritize rapid disintegration, dose uniformity at the 2.5 mg strength, chemical stability, palatability, and manufacturing cost.

What is the FDA status of midodrine hydrochloride?

Midodrine hydrochloride is an orally administered prodrug indicated for symptomatic orthostatic hypotension. It is converted to the active metabolite desglymidodrine, an alpha-1 adrenergic agonist. FDA labeling warns that the drug can cause marked supine hypertension, which limits dosing flexibility and affects the commercial value of extended-release or rapid-delivery concepts.[1]

Attribute	Midodrine hydrochloride
Active ingredient	Midodrine hydrochloride
Active metabolite	Desglymidodrine
Primary indication	Symptomatic orthostatic hypotension
Common strengths	2.5 mg, 5 mg, 10 mg
Common dosage form	Immediate-release oral tablet
Typical administration	Three times daily during waking hours
Bedtime restriction	Last dose generally taken at least 3 to 4 hours before bedtime
Regulatory category	Small-molecule prescription drug
Biosimilar exposure	None
Primary commercial competitors	Generic midodrine tablet manufacturers
Principal safety issue	Supine hypertension

The original ProAmatine product is no longer the main commercial reference point. The market is primarily supplied by generic manufacturers, creating price pressure and reducing the value of ordinary tablet reformulation.

What excipients are used in midodrine hydrochloride tablets?

Commercial midodrine hydrochloride tablets generally use conventional immediate-release excipients. Public labeling for generic products identifies excipient classes such as microcrystalline cellulose, pregelatinized starch or other starch derivatives, povidone, crospovidone, colloidal silicon dioxide, and magnesium stearate.[2]

The exact composition varies by manufacturer, strength, supplier, and manufacturing process. These excipients are not interchangeable from a regulatory or performance perspective.

Excipient class	Primary function	Relevance to midodrine formulation
Microcrystalline cellulose	Diluent and dry binder	Supports tablet strength and compressibility
Pregelatinized starch	Binder and disintegrant	Useful for direct compression or wet granulation
Crospovidone	Superdisintegrant	Supports rapid tablet breakup
Povidone	Binder	Improves granule cohesion and content uniformity
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and reduces processing variability
Magnesium stearate	Lubricant	Controls ejection force but can slow wetting if overused
Film-coating polymers	Protection, identification, swallowability	Can improve handling and reduce tablet odor or taste
Colorants	Product identification	Relevant to strength differentiation and medication safety

Midodrine hydrochloride is a potent active pharmaceutical ingredient relative to the tablet mass. The 2.5 mg strength is the most demanding from a content-uniformity perspective. Low-dose manufacturing may require ordered mixing, geometric dilution, wet granulation, or other process controls rather than simple blending.

How should an excipient strategy be designed for midodrine HCl tablets?

The best baseline strategy is a low-cost, immediate-release tablet with fast and reproducible disintegration.

Prioritize dose uniformity at 2.5 mg

The lowest strength can create segregation risk during blending, transfer, and compression. A formulation should use excipients with compatible particle size and density profiles. Microcrystalline cellulose and pregelatinized starch can support blend uniformity, but excessive differences in particle morphology may increase segregation during hopper residence and tablet press feeding.

Potential controls include:

• ordered addition of midodrine hydrochloride to a portion of the diluent;
• controlled blending time;
• low-shear transfer;
• narrow particle-size distributions;
• in-process blend and tablet assay testing;
• validated sampling plans for low-dose uniformity.

A high-cost specialty excipient is unlikely to create sufficient commercial value in a standard tablet unless it materially improves content uniformity, dissolution, or manufacturing yield.

Maintain rapid disintegration

Midodrine is administered as an immediate-release product. A formulation that disintegrates slowly could delay exposure and create unnecessary bioequivalence risk. Crospovidone, croscarmellose sodium, or sodium starch glycolate can be evaluated as superdisintegrants. The preferred choice will depend on compression force, tablet porosity, lubricant level, and moisture exposure.

Magnesium stearate should be optimized rather than maximized. Excessive lubrication can produce hydrophobic tablet surfaces, slower wetting, and slower dissolution. The risk is more pronounced when blending time is long or when the formulation has low porosity.

Control moisture without over-drying the tablet

Midodrine hydrochloride formulations must be assessed for hygroscopicity, chemical degradation, dissolution drift, and tablet-hardness changes. Colloidal silicon dioxide can improve powder flow and help manage small amounts of moisture, but it is not a substitute for packaging or stability controls.

A practical commercial design would pair a conventional excipient system with:

• low-moisture manufacturing conditions;
• aluminum-aluminum blister packaging where justified;
• high-barrier bottles with desiccant when bottle economics are preferable;
• tablet friability controls;
• accelerated and long-term stability testing;
• packaging compatibility studies.

What formulations are protected by midodrine excipient opportunities?

The most commercially relevant opportunities are not likely to come from a new inactive ingredient alone. They are more likely to come from a complete dosage-form and manufacturing package that solves a specific patient or supply problem.

Immediate-release tablets

The standard tablet remains the lowest-risk option. Differentiation can come from:

• 2.5 mg dose precision;
• smaller tablet size;
• improved swallowability;
• reduced friability;
• color-coded strengths;
• calendar or unit-dose packaging;
• reliable supply to retail and institutional channels.

A tablet that is materially smaller may improve adherence for older patients, but reducing tablet mass can make content uniformity and compression performance more difficult at the 2.5 mg strength.

Orally disintegrating tablets

An orally disintegrating tablet could target patients with dysphagia or poor access to water. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and suitable compression aids are common development candidates for this type of product.

The clinical value is limited by the existing rapid absorption of midodrine and by the risk of supine hypertension. An ODT would need to demonstrate a meaningful patient-use benefit without producing clinically important changes in exposure or timing. A rapid-delivery profile could create regulatory and safety concerns rather than a clear commercial advantage.

Oral liquid

An oral solution or suspension could support patients who cannot swallow tablets, patients requiring feeding-tube administration, and dose titration below or between marketed tablet strengths.

Candidate excipient categories include:

• purified water;
• pH control agents;
• sweeteners;
• flavors;
• viscosity modifiers;
• preservatives, if justified;
• chelating or antioxidant systems where stability data support their use.

Taste masking is a central technical issue. Midodrine hydrochloride is a salt form, and an oral liquid may have an acidic or bitter taste profile. A successful product would need a palatable system that remains stable across the labeled shelf life.

An oral solution also introduces risks involving microbial control, preservative effectiveness, container dosing accuracy, precipitation, adsorption to feeding-tube materials, and dose carryover in oral syringes.

Sprinkle or multiparticulate dosage form

A multiparticulate product could provide a dysphagia-oriented option without requiring a fully dissolved liquid. The main challenges are taste masking, dose recovery, content uniformity, and administration with soft food or liquids.

The product must define whether the particles can be crushed, chewed, mixed with food, or delivered through a feeding tube. These instructions would require product-specific compatibility and performance data.

Modified-release formulations

Modified-release midodrine products have weaker commercial logic. The standard regimen is constrained by supine hypertension and bedtime dosing restrictions. Extending exposure into nighttime hours could conflict with the drug’s safety profile.

A modified-release product would face pharmacokinetic, clinical, and labeling challenges. Its value would depend on solving a specific adherence problem without increasing nocturnal blood pressure risk. The product would likely require a more demanding regulatory strategy than a conventional generic tablet.

When does midodrine lose exclusivity?

Midodrine hydrochloride is a mature small-molecule product. The principal branded-product exclusivity period has expired, and generic tablets are commercially available in the United States. The relevant competitive question is therefore not the loss of basic compound exclusivity but whether a new formulation has its own patent, regulatory exclusivity, or market-access barrier.

Exclusivity category	Commercial assessment
Original compound patent	Expired or no longer commercially limiting
Branded product exclusivity	Expired
Generic tablet entry	Established
Biosimilar pathway	Not applicable
New formulation patents	Possible, but must claim a defensible technical result
Method-of-use patents	Possible, but vulnerable if based only on known dosing or indication
Regulatory exclusivity for a new product	Product- and pathway-specific
Orange Book impact	Depends on listed patents for the specific approved product

Current Orange Book entries and patent listings should be evaluated for the exact reference product and any new formulation under development. A generic tablet developer would ordinarily focus on pharmaceutical equivalence, bioequivalence, manufacturing economics, and supply reliability rather than relying on compound-level exclusivity.[3]

How does the FDA pathway affect commercial opportunities?

A conventional midodrine hydrochloride tablet may be eligible for an abbreviated new drug application if it meets the applicable requirements for pharmaceutical equivalence and bioequivalence to the reference product. The formulation should generally align with the reference product’s dosage form, strength, route, and release characteristics.[4]

A novel oral liquid, ODT, sprinkle product, or modified-release formulation may require a different regulatory analysis. Depending on the product design and reference product, development could involve:

• an ANDA with a formulation that satisfies applicable equivalence requirements;
• a 505(b)(2) application relying partly on published literature or prior FDA findings;
• a new clinical pharmacology package;
• comparative pharmacokinetic studies;
• food-effect evaluation;
• in vitro dissolution and dosage-form performance studies;
• additional safety or clinical data.

The regulatory pathway should be selected after assessing whether the new dosage form is pharmaceutically equivalent to an approved product. A novel excipient or materially different route of administration would increase regulatory complexity.

What is the Orange Book and Paragraph IV risk for midodrine?

For the mature tablet market, Paragraph IV risk is generally associated with patents listed against a specific reference product rather than with the historical midodrine compound itself. A challenger must assess:

• listed patents for the relevant reference product;
• expiration dates and pediatric extensions;
• formulation and method-of-use claims;
• whether a certification is required;
• potential 30-month-stay exposure;
• exclusivity held by any first ANDA applicant;
• litigation involving the applicable NDA holder.

A formulation developer seeking protection should avoid narrow claims that merely recite routine excipients. Stronger claims would require a measurable technical result, such as improved stability, reduced degradation, controlled dissolution, enhanced dose uniformity, or a defined administration system for dysphagia patients.

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barriers are operational rather than molecule-specific.

Manufacturing barriers

The main risks are:

1. low-dose blend uniformity at 2.5 mg;
2. segregation during transfer and compression;
3. dissolution slowdown from lubricant overuse;
4. moisture-related stability changes;
5. tablet chipping and friability;
6. scale-up differences between laboratory and commercial compression;
7. analytical sensitivity for low-dose assay and impurities.

A formulation with a simple excipient system may have stronger commercial economics than a complex system if it delivers equivalent stability and dissolution with fewer suppliers and fewer process steps.

Intellectual-property barriers

Potential patentable areas include:

• defined excipient ratios;
• specific particle-size distributions;
• low-moisture compositions;
• improved stability profiles;
• orally disintegrating systems;
• taste-masked multiparticulates;
• liquid formulations with defined pH and preservative systems;
• feeding-tube-compatible compositions;
• packaging and dosing systems tied to measurable performance.

Method-of-use claims based solely on treating orthostatic hypotension are less likely to provide durable differentiation where the indication and dosing principles are already established. Claims should be linked to a new formulation, patient population, administration method, or clinically meaningful outcome.

Which companies are challenging or competing with midodrine products?

The commercial market is fragmented among generic manufacturers rather than dominated by a single branded company. Competition typically centers on:

• tablet price;
• product availability;
• wholesaler and pharmacy contracts;
• ability to supply all three strengths;
• manufacturing redundancy;
• packaging formats;
• back-order performance;
• regulatory compliance.

The market has no biosimilar competition because midodrine hydrochloride is a small molecule. There is also limited strategic value in developing a conventional branded tablet unless the sponsor has a differentiated distribution channel, a specialty-pharmacy strategy, or a formulation that addresses dysphagia and dose titration.

What commercial opportunities have the highest probability of success?

Opportunity	Patient need	Development risk	Commercial outlook
Low-cost 2.5/5/10 mg tablets	Reliable access and dose titration	Low	High volume, low margin
Smaller swallowable tablet	Older adults and dysphagia	Low to moderate	Moderate differentiation
ODT	Administration without water	Moderate	Niche opportunity
Oral solution	Dysphagia, feeding tubes, dose flexibility	Moderate to high	Potentially attractive specialty product
Sprinkle multiparticulate	Patients unable to swallow tablets	High	Niche, defensible if well designed
Modified release	Reduced dosing frequency	High	Uncertain because of hypertension risk
Unit-dose blister pack	Adherence and institutional use	Low	Moderate commercial value
Pediatric formulation	Weight-based dosing	High	Requires careful regulatory and clinical positioning

The strongest near-term strategy is a dual portfolio: a cost-optimized conventional tablet for broad generic distribution and a liquid or dysphagia-oriented product for specialty channels. The latter can support higher pricing if it demonstrates reliable dose delivery, acceptable taste, stability, and practical administration.

What revenue exposure and pricing dynamics should investors expect?

Public disclosures generally do not isolate midodrine revenue by product, manufacturer, or formulation. The conventional tablet market should be treated as a mature generic category with substantial price competition and limited brand loyalty.

Revenue upside is more likely to come from:

• shortage-resistant supply;
• contract manufacturing;
• institutional purchasing;
• specialty pharmacy distribution;
• differentiated dosage forms;
• multi-strength portfolios;
• packaging that reduces dispensing errors.

A new product should not be valued solely on the size of the orthostatic hypotension population. The addressable opportunity depends on the number of patients unable to use tablets, the willingness of payers to reimburse a differentiated product, and whether the formulation receives meaningful substitution protection.

How strong is the midodrine patent estate?

The historical midodrine patent estate has limited relevance to ordinary generic tablets. Patent strength for a new product would depend on claim scope and technical evidence.

Patent strategy	Expected strength
Broad compound claim	Low for new entrants because the active ingredient is mature
Routine tablet excipient combination	Low
Narrow composition-of-matter formulation claim	Moderate if supported by data
Stability-improvement claim	Moderate to strong if reproducible and non-obvious
Taste-masked liquid or multiparticulate claim	Moderate
Feeding-tube administration claim	Moderate if supported by compatibility data
Modified-release claim	Potentially strong, but high clinical and regulatory risk
Packaging-only claim	Usually limited unless linked to a specific dosing or stability result

Key Takeaways

• Midodrine hydrochloride is a mature generic small molecule with no biosimilar risk.
• Conventional tablets are commercially accessible but exposed to price competition.
• The 2.5 mg strength creates the greatest content-uniformity and manufacturing challenge.
• Crospovidone, starch derivatives, microcrystalline cellulose, povidone, colloidal silicon dioxide, and magnesium stearate are practical excipient building blocks.
• Oral liquids, ODTs, and multiparticulates offer the clearest formulation-based differentiation.
• Modified-release products face a difficult risk-benefit analysis because of supine hypertension and bedtime dosing restrictions.
• New patents should claim measurable formulation or administration benefits rather than routine excipient mixtures.
• The strongest commercial model combines a low-cost tablet portfolio with a specialty dosage form for dysphagia, feeding-tube administration, or flexible dosing.
• Current Orange Book listings, FDA exclusivity data, and litigation dockets must be assessed against the specific reference product and proposed dosage form.

FAQs

Is midodrine hydrochloride suitable for an oral liquid product?

Yes. An oral liquid could address dysphagia, feeding-tube administration, and dose titration, but taste, stability, preservative effectiveness, dosing accuracy, and tube compatibility would determine its commercial viability.

Which excipient is most important for midodrine tablet disintegration?

No single excipient determines performance. A superdisintegrant such as crospovidone, croscarmellose sodium, or sodium starch glycolate must be balanced with tablet porosity, compression force, binder level, and magnesium stearate concentration.

Does midodrine have biosimilar competition?

No. Midodrine hydrochloride is a small-molecule drug and competes through generic drug pathways rather than the biosimilar pathway.

Could an ODT midodrine product obtain premium pricing?

Potentially, but the premium would depend on demonstrated patient-use value. The product would need to show meaningful benefits for dysphagia or administration without water while maintaining acceptable pharmacokinetic and blood-pressure characteristics.

What is the most defensible patent strategy for a new midodrine formulation?

The strongest strategy would usually combine composition, manufacturing, and administration claims supported by data showing improved stability, dissolution, dose uniformity, taste masking, or feeding-tube performance.

References

1. U.S. Food and Drug Administration. (2023). Midodrine hydrochloride tablets prescribing information. DailyMed, National Library of Medicine.

2. U.S. National Library of Medicine. (2024). Midodrine hydrochloride tablet drug labels. DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. Center for Drug Evaluation and Research.